AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9282968
Drug: Aflurax (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflurax (1200 mg, two tablets four times daily for 4 weeks)
Trial: 9282968
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets four times daily for 4 weeks)
Trial: 2433098
Drug: Oral hydromorphone
RxNorm normalized name: hydromorphone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydromorphone hydrochloride 2 mg
Trial: 28679555
Drug: Juice supplemented
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juice supplemented with 15 μg vitamin D2
Trial: 28679555
Drug: Biscuit supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biscuit supplemented with 15 μg vitamin D2
Trial: 21080844
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cell treatment)
Trial: 16932286
Drug: Alendronate and
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate and risedronate (oral nitrogen-containing bisphosphonates)
Trial: 9550632
Drug: NG‐monomethyl‐L‐arginine (L‐NMMA,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐monomethyl‐L‐arginine (L‐NMMA, 3 mg/kg priming dose plus 3 mg/kg/h) for 3 hours
Trial: 3276343
Drug: Amoxicillin-clavulanate (Augmentin)
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (Augmentin)
Trial: 29032666
Drug: Fimasartan 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 30 mg
Trial: 25850881
Drug: Fimasartan 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 30 mg/Amlodipine 5 mg
Trial: 25850881
Drug: Fimasartan 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 30 mg/Amlodipine 10 mg
Trial: 25850881
Drug: Fimasartan 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 60 mg/Amlodipine 5 mg
Trial: 21242819
Drug: EPT (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPT (50 μg transdermal estradiol daily and 200 mg/d micronized progesterone for the first 14 days of each month; n = 21)
Trial: 21242819
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg daily; n = 17)
Trial: 21242819
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment; n = 21)
Trial: 9343463
Drug: EGb (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb (120 mg/d)
Trial: 3024689
Drug: Triprolidine 10
RxNorm normalized name: phenylephrine HCl/triprolidine 10 mg-2.5 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine 10 mg (active control)
Trial: 27261562
Drug: Clinician-guided Cognitive
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-guided Cognitive Behaviour Therapy (CG‐CBT)
Trial: 27261562
Drug: Self-guided Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-guided Cognitive Behaviour Therapy (SG‐CBT)
Trial: 25173752
Drug: GLP-2 administration
RxNorm normalized name: (Gly2)GLP-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-2 administration
Trial: 25173752
Drug: GLP-2 administration
RxNorm normalized name: (Gly2)GLP-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-2 administration 7 hours after a high-fat meal
Trial: 20685494
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal system (BTDS) 10 to 40 microg/h
Trial: 18435869
Drug: Standard psychiatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard psychiatric out-patient treatment (Control)
Trial: 15939681
Drug: GIK solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK solution (300 g glucose + 50 IU crystallized insulin + 80 mEq potassium chloride in one liter solution)
Trial: 6137856
Drug: Alprazolam 1.5-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 1.5-3 mg per day
Trial: 6137856
Drug: Diazepam 15-30
RxNorm normalized name: diazepam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 15-30 mg per day
Trial: 31863809
Drug: Surface treatment
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surface treatment
Trial: 31863809
Drug: CFU/mL
RxNorm normalized name: mumps skin test antigen 40 CFU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFU/mL
Trial: 17430323
Drug: Saline 0.9%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9%, 2 ml
Trial: 1328366
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment based on weight reduction and sodium restriction
Trial: 23156846
Drug: 0.1% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tacrolimus (FK‐506) eye ointment
Trial: 19167587
Drug: Rosiglitazone hydrochloride
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone hydrochloride (test formulation)
Trial: 14508308
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg intravenous M6G
Trial: 14508308
Drug: 0.13 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.13 mg/kg intravenous morphine
Trial: 8973852
Drug: Chemotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy after the first trimester of pregnancy
Trial: 1866057
Drug: A‐HDF (1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A‐HDF (1.75 mmol/l calcium)
Trial: 25509255
Drug: Shuxuening Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxuening Injection (SI) 15 mL, twice daily for 14 days
Trial: 22574591
Drug: Shuxuening Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxuening Injection (SI)
Trial: 7105431
Drug: Intravenous labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous labetalol (100 mg)
Trial: 17302079
Drug: Intranasal meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal meperidine
Trial: 25972155
Drug: Intranasal butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal butorphanol
Trial: 15034108
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy with conjugated estrogens and medroxyprogesterone acetate
Trial: 19210012
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD)
Trial: 28161016
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (cold wall oxygen 100% via infant nasal cannulae at low flow to a maximum of 2 L/min)
Trial: 26525809
Drug: Basic (standard)
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic (standard) treatment (B vitamins, lipoic acid)
Trial: 25006405
Drug: Oral tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tadalafil (40 mg daily for 12 months)
Trial: 16510377
Drug: Fluvastatin XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin XL 80 mg once daily
Trial: 8314497
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interferon alfa‐2b (10 million units three times weekly subcutaneously for 16 weeks) after six weeks of prednisone (followed by a two week drug-free period)
Trial: 8314497
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interferon alfa‐2b
Trial: 2967932
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (5 micrograms)
Trial: 2967932
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (5 micrograms) plus immunoglobulin (0.25 ml/kg)
Trial: 29941402
Drug: Experimental moisturizing
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental moisturizing mouthwash (1 to 2 doses/day for 8 days)
Trial: 15576394
Drug: COC and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COC and metformin (1500 mg/day) for 6 months
Trial: 7623902
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and glyburide (protocol 2)
Trial: 7623902
Drug: Metformin (protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (protocol 1)
Trial: 7261663
Drug: Topical thrombin
RxNorm normalized name: thrombin Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical thrombin
Trial: 31415033
Drug: everolimus (mTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: everolimus (mTOR inhibitor)
Trial: 23869233
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg kg(-1) day(-1))
Trial: 16461311
Drug: Intermittent subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent subcutaneous low-dose IL-2
Trial: 10365634
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 mg/d)
Trial: 10365634
Drug: Clomipramine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (75 mg/d)
Trial: 8963484
Drug: Oral dexniguldipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexniguldipine (750 mg/d, 1,500 mg/d, 2,250 mg/d) for 3 consecutive weeks
Trial: 8963484
Drug: Intravenous dexniguldipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexniguldipine (2 mg/kg body weight)
Trial: 8963484
Drug: Oral dexniguldipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexniguldipine
Trial: 1882877
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy review alone (control group)
Trial: 10323113
Drug: Methadone 10
RxNorm normalized name: normethadone 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 10 mg
Trial: 26659582
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (500 μg bid)
Trial: 21697535
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA) 4.5 g/d
Trial: 19128672
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lansoprazole daily
Trial: 10869264
Drug: Sitaxsentan (1.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxsentan (1.5, 3.0, or 6.0 mg/kg)
Trial: 1413921
Drug: ACTH-related hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH-related hormones
Trial: 1413921
Drug: Corticotropin releasing-hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin releasing-hormone
Trial: 6368241
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MCP) given i.v. in 4 doses of 1 mg/kg over a period of 4 1/2 hr
Trial: 6368241
Drug: Dexamethazone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethazone (DXM) administered i.m. in 4 doses of 8 mg over 24 hr and another 10 mg i.v. just prior to CDDP administration
Trial: 30514352
Drug: Weekly one-hour
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly one-hour multi-component training session within a WHPP over a one-year period
Trial: 23996739
Drug: Domperidone syrup
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone syrup 0.15 mL/kg three times a day for 3 months along with PEG solution 0.6 g/kg/day two times a day for 6 months
Trial: 31542082
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg per week starting from the first day after menstruation
Trial: 24600231
Drug: Pantethine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantethine (600 mg/day from weeks 1 to 8 and 900 mg/day from weeks 9 to 16)
Trial: 17697903
Drug: Extended-release metformin
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release metformin (MER) plus sulfonylurea (glyburide)
Trial: 9506323
Drug: Withdrawal from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal from digoxin therapy
Trial: 29326331
Drug: Low-flow oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow oxygen therapy (LFO2) for 2 months
Trial: 27190087
Drug: Linagliptin plus
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin plus pioglitazone 15 mg
Trial: 22409999
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin administration to keep blood glucose between 6 and 8 mmol/l during surgery (n = 9)
Trial: 20959577
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil capsules (800 mg/d of DHA)
Trial: 20959577
Drug: Vegetable oil
RxNorm normalized name: Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable oil capsules without DHA (control)
Trial: 9087976
Drug: Selegiline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline and alpha-tocopherol treatment
Trial: 8403805
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose loading
Trial: 3288525
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of clavulanate‐potentiated amoxycillin (1200 mg) 2 hours before surgery
Trial: 3288525
Drug: Intravenous cefotaxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefotaxime (2 g each) in three doses during surgery, and 6 and 12 hours after surgery
Trial: 28751300
Drug: 10-week Internet-based
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-week Internet-based guided self-help program with weekly therapist support via encrypted email
Trial: 23052541
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg of 20% mannitol 150 min after the initiation of pneumoperitoneum
Trial: 19029316
Drug: Posaconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (400 mg twice daily)
Trial: 25179689
Drug: APF530 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APF530 500 mg
Trial: 16968847
Drug: Wait-and-see prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-and-see prescription (WASP)
Trial: 18753749
Drug: Restorations with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restorations with leakage (L+)
Trial: 12492754
Drug: Motivational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motivational intervention (treatment as usual plus a one-session brief motivational intervention)
Trial: 8940324
Drug: Alcohol ingestion
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol ingestion (0.7 g/kg) in control women not on ERT
Trial: 24818590
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to low dose aspirin and heparin
Trial: 23182016
Drug: Red-light treatment
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red-light treatment (n = 10)
Trial: 18316154
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 20% CO2-enriched air as unconditioned stimulus (US) during acquisition trials.
Trial: 12055112
Drug: 1% escin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% escin gel
Trial: 12055112
Drug: 2% escin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% escin gel
Trial: 11064625
Drug: succinylcholine 1
RxNorm normalized name: Succinylcholine 124 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine 1 mg kg‐1
Trial: 29452684
Drug: Pimavanserin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin (two 17 mg tablets daily)
Trial: 24159051
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (n = 14)
Trial: 12560443
Drug: Pegfilgrastim 100
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim 100 micro g/kg (single subcutaneous injection)
Trial: 12560443
Drug: Filgrastim 5
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim 5 micro g/kg (daily subcutaneous injections)
Trial: 31445316
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (2.5 g/d for 45 days)
Trial: 29386889
Drug: UMEC 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC 62.5 μg
Trial: 27103795
Drug: TIO 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIO 18 μg
Trial: 24568323
Drug: Medications for
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications for pain relief
Trial: 16278614
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of micronized estradiol (n = 85)
Trial: 16278614
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated equine estrogens (n = 85)
Trial: 10205099
Drug: Itraconazole 400
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole 400 mg a day for 1 week in every 4 weeks for 16 weeks (I4)
Trial: 20308833
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg gestrinone
Trial: 30366744
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine and haloperidol
Trial: 30366744
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine with normal saline (Control)
Trial: 19734176
Drug: Budesonide/formoterol (320/9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (320/9 microg, one inhalation twice daily)
Trial: 17552386
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sub-Tenon's space injection)
Trial: 11510013
Drug: Rabbit antithymocyte
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit antithymocyte globulin (RATG) induction at a dose of 1.5 mg/kg IV
Trial: 11510013
Drug: Methylprednisolone, 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone, 1,000 mg IV
Trial: 9576460
Drug: Duodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duodenal infusion of heparinized autologous blood
Trial: 3499211
Drug: Cytosine arabinoside/cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytosine arabinoside/cyclophosphamide pulses every eight weeks during continuation therapy
Trial: 26056191
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg propafenone
Trial: 23621906
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood injection
Trial: 2863220
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg once a day)
Trial: 12585167
Drug: Conventional plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional plus Salvia Injection (SI) intervention treated group (24 cases)
Trial: 12585167
Drug: Conventional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional steroid treated group (20 cases)
Trial: 10368505
Drug: Tocolytic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocolytic agents used in abruptio placentae group (95 women, 73%)
Trial: 10368505
Drug: Tocolytic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocolytic agents used in placenta previa group (78 patients, 72%)
Trial: 10368505
Drug: Tocolytic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocolytic agents (combined patients: 171)
Trial: 10368505
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not treated with tocolytic agents)
Trial: 7025874
Drug: Pethidine 50
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 50 mg
Trial: 2040318
Drug: Heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone (Control)
Trial: 2040318
Drug: Decrease of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease of sigma-ST at 2 h post-treatment